Physician profile
Man Ton
NPI 1700097425
$3,944.87
in general payments reported to CMS, 2019-2025
21 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.37 · 2022: $477 · 2023: $337 · 2024: $768 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,455.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $827.15 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Novo Nordisk INC | $624.00 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $430.25 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $357.87 | 2022-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $303.74 | 2023-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $292.64 | 2022-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $164.42 | 2024-2025 | |
| Astellas Pharma US INC | $149.92 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $139.99 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.48 | 2023-2025 | Jardiance, Jascayd |
| Exact Sciences Corporation | $137.47 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $101.83 | 2024-2025 | |
| Organon LLC | $53.66 | 2022 | |
| Si-Bone, INC. | $40.68 | 2025 | |
| Idorsia Pharmaceuticals US INC | $40.18 | 2024 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.72 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $31.13 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Glaxosmithkline, LLC. | $30.16 | 2022-2025 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $18.08 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $17.13 | 2024 | |
| Genentech USA, INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Man Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.